Association for Human Pharmacology in the Pharmaceutical Industry Christmas Lecture

Event Date:
15 December 2020, 14:00 – 16:30 (GMT)
Location:
Virtual Meeting
View ProgramView Program

The Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI) is a membership organisation for professionals working within early drug development. The annual Christmas Lectures provide an opportunity for members to learn from industry experts and peers.

This year’s lectures will include a presentation by Richmond Pharmacology’s CEO and Founder, Jorg Taubel M.D.

Throughout 2020, Richmond Pharmacology quickly adapted recruitment and operational processes to safeguard research participants, staff and visitors to the London-based clinical research unit. Dr Taubel will share the new operating model for the COVID-secure facility and share lessons learned during this process.  

To attend the Christmas Lectures, please register here: https://cconline.eventsair.com/ahppi/ahppi2020/Site/Register

A summary of discussions of the 2019 annual meeting, which focused on impending change, innovation and future challenges, has been published. Read more in Frontiers in Pharmacology.


Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more